FDA 483 - Giora Weisz MD - October 24, 2019

An FDA inspection of Giora Weisz MD in Bronx, NY, identified a significant deviation from the investigational plan. The firm failed to adhere to protocol for scheduled laboratory assessments and did not properly follow exclusion criteria for study subjects. This indicates a lack of compliance with established clinical trial procedures.